Psoriasis

Make the diagnosis clinically when sharply demarcated scaly plaques have a typical symmetric distribution involving scalp, extensor elbows or knees, lumbosacral skin, or flexures. Document morphology and distribution before treatment because plaque psoriasis accounts for approximately 80% to 90% of cases and may coexist with nail or fold disease that changes topical formulation and potency selection. WHO+1WHO1. Application to Add Ustekinumab to the ...WHO[PDF] Application for inclusion of calcipotriol (calcipotriene)

Obtain a skin biopsy when the morphology or distribution is atypical, when an alternative papulosquamous disorder remains plausible, or when erythrodermic or pustular disease creates diagnostic uncertainty. Histopathology can complement the clinical diagnosis but is not routine for characteristic plaque psoriasis. WHO+1WHO[PDF] 29 October 2024 WHO Expert Committee on the Selection and Use ...WHO1. Application to Add Ustekinumab to the ...

Treat generalized erythroderma as an urgent dermatologic presentation. It may arise from progressive confluent plaque disease or unstable psoriasis precipitated by infection, medications, or corticosteroid withdrawal, and can cause hypothermia, hypoalbuminemia, anemia, and nutrient loss. WHOWHO[PDF] 29 October 2024 WHO Expert Committee on the Selection and Use ... Evaluate for precipitating infection or medication exposure and arrange urgent specialty management rather than escalating outpatient topical therapy alone. WHOWHO[PDF] 29 October 2024 WHO Expert Committee on the Selection and Use ...

Record BSA and a reproducible activity measure such as PASI or PGA at baseline and before changing treatment. PASI incorporates plaque erythema, induration, scaling, and involved surface area across the head and neck, trunk, and upper and lower limbs; PGA, BSA, DLQI, and nail scores can complement PASI when the disease phenotype or practice workflow makes PASI less practical. WHOWHO[PDF] 29 October 2024 WHO Expert Committee on the Selection and Use ...

Use severity measures to guide, not replace, clinical judgment. A PASI of at least 10 or BSA of at least 10% with DLQI greater than 10 is a commonly used severe-disease threshold, while dermatology referral criteria also identify BSA greater than 10%, PASI greater than 10, or DLQI greater than 10 as moderate-to-severe disease. Wolters Kluwer+1Wolters KluwerBiologics and Biosimilars in Psoriasis : Indian Journal of DermatologyPubMedPlaque Psoriasis - StatPearls - NCBI Bookshelf Lesions on the scalp, face, flexures, hands, feet, genitals, or nails can justify escalation despite limited BSA when symptoms, function, or treatment feasibility are disproportionate. Site and symptom burden are explicit components of severity assessment. WHO+1WHO[PDF] 29 October 2024 WHO Expert Committee on the Selection and Use ...WHO[PDF] Application for inclusion of calcipotriol (calcipotriene)

Use topical treatment for mild or limited psoriasis, particularly when disease can be treated reliably by the patient. Topical corticosteroids and vitamin D analogues are the core first-line options for limited disease. BMJ+2BMJPsoriasis - Symptoms, diagnosis and treatment | BMJ Best Practice USBMJPsoriasis - Symptoms, diagnosis and treatment | BMJ Best Practicestaging aadPsoriasis clinical guideline If disease is extensive, cannot be practically treated with topical therapy, remains uncontrolled despite an adherent topical regimen, or produces substantial functional or quality-of-life burden, assess candidacy for phototherapy or systemic treatment. staging aad+2staging aadPsoriasis clinical guidelineaadPsoriasis clinical guideline - American Academy of DermatologyPubMedPlaque Psoriasis - StatPearls - NCBI Bookshelf

For limited psoriasis, select a topical corticosteroid, a vitamin D analogue, or their combination according to lesion thickness, anatomic site, cosmetic acceptability, and ability to apply treatment consistently. AAD-NPF guidance addresses topical agents and severity measurement, and BMJ Best Practice identifies topical corticosteroids and/or vitamin D analogues as treatment for mild or limited disease. BMJ+1BMJPsoriasis - Symptoms, diagnosis and treatment | BMJ Best Practice USstaging aadPsoriasis clinical guideline

For scalp psoriasis, use topical therapy in a formulation the patient can apply through hair-bearing skin. When a potent corticosteroid or vitamin D analogue used for up to 8 weeks does not achieve clearance, near-clearance, or satisfactory control, an adult can receive a very potent corticosteroid up to twice daily for 2 weeks; coal tar once or twice daily and specialist support with application technique are alternatives. nice org uknice org uk[PDF] Appendix A: Summary of evidence from surveillance | NICE Vitamin D analogue monotherapy is most appropriate when corticosteroids cannot be used at that site or for mild-to-moderate scalp disease. nice org uknice org uk[PDF] Appendix A: Summary of evidence from surveillance | NICE

Move beyond topical monotherapy when distribution makes application burdensome or when objective activity and patient-reported burden remain unacceptable despite a coherent regimen. Phototherapy is addressed in AAD-NPF psoriasis guidance and is an appropriate treatment-domain consideration before or alongside systemic options based on disease extent, access, and patient preference. BMJ+2BMJPsoriasis - Symptoms, diagnosis and treatment | BMJ Best Practicestaging aadPsoriasis clinical guidelinePubMedPlaque Psoriasis - StatPearls - NCBI Bookshelf

For adults with moderate-to-severe psoriasis, AAD-NPF guidance supports methotrexate and apremilast as systemic nonbiologic options; methotrexate is less effective for cutaneous psoriasis than adalimumab and infliximab. aadaadPsoriasis clinical guideline - American Academy of Dermatology Cyclosporine and acitretin are also addressed within systemic nonbiologic treatment guidance. PubMedPubMedJoint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies - PubMed Select among these approaches according to urgency of control, reproductive considerations, hepatic and renal risk, comorbid inflammatory disease, treatment burden, and monitoring capacity; the available guideline summary does not establish a universal sequence among systemic agents. PubMed+1PubMedJoint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies - PubMednice org uk[PDF] Psoriasis Guideline Consultation Comments Table - NICE

Biologic therapy is a treatment option for adults with moderate-to-severe psoriasis, including TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibition, and IL-23 inhibitors. aad+1aadPsoriasis clinical guideline - American Academy of DermatologyPubMedBiologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review After inadequate response to a first biologic, switching to a second biologic is a guideline-supported strategy; biologic plus methotrexate is another possible approach, although psoriasis-specific evidence for combination treatment is limited. PubMedPubMedTreatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines - PMC

Before initiating a biologic, obtain a focused infection history and physical examination and screen for latent tuberculosis infection. PubMedPubMedBiologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review Screen for viral infections, including HIV and hepatitis, before biologic therapy as described in psoriasis management recommendations; withhold biologic treatment during a major infection. PubMedPubMedRecommendations for Management of Childhood Psoriasis - PMC Incorporate inflammatory bowel disease, congestive heart failure, multiple sclerosis, hepatitis B, prior nonmelanoma skin cancer, lymphoma, and latent tuberculosis into biologic selection because these conditions materially alter class-specific risk assessment. PubMedPubMedBiologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review

Screen for psoriatic arthritis at psoriasis visits by asking about inflammatory joint pain, prolonged stiffness, swollen digits, heel or other entheseal pain, back symptoms, and functional limitation; examine for swollen joints, dactylitis, enthesitis, and nail disease. Approximately 30% of patients with cutaneous psoriasis in dermatology clinics have rheumatologist-diagnosed psoriatic arthritis. BMJBMJPsoriasis - Symptoms, diagnosis and treatment | BMJ Best Practice US Refer suspected inflammatory musculoskeletal disease to rheumatology because psoriatic arthritis is potentially debilitating and requires targeted treatment with ongoing monitoring. PubMedPubMedPsoriatic Arthritis - StatPearls - NCBI Bookshelf

Treat psoriasis as a multisystem disease and address cardiovascular risk factors rather than focusing only on plaque clearance. Psoriasis and psoriatic arthritis are epidemiologically linked to cardiovascular risk factors and increased cardiovascular disease risk, while psoriatic arthritis is associated with hypertension, metabolic syndrome, obesity, hyperlipidemia, diabetes mellitus, and cardiovascular disease. aad+2aadPsoriasis clinical guideline - American Academy of DermatologyPubMedCardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. - AbstractPubMedPsoriatic Arthritis - StatPearls - NCBI Bookshelf Measure and manage blood pressure, weight, glycemic status, and lipids according to standard primary-care and cardiovascular-prevention pathways.

Ask about inflammatory bowel symptoms and ocular symptoms when musculoskeletal disease is present. Inflammatory bowel disease, particularly Crohn disease, is associated with increased risk of psoriatic arthritis, and uveitis requires ophthalmologic evaluation and treatment. PubMedPubMedPsoriatic Arthritis - StatPearls - NCBI Bookshelf These findings should influence biologic-class selection and coordination with gastroenterology, rheumatology, or ophthalmology. PubMed+1PubMedBiologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A ReviewPubMedPsoriatic Arthritis - StatPearls - NCBI Bookshelf